Evergreen Capital Management LLC Sells 2,786 Shares of Becton, Dickinson and Company $BDX

Key Points

• Evergreen Capital Management LLC has reduced its stake in Becton, Dickinson and Company by 5.5%, selling 2,786 shares, now owning a total of 47,905 shares worth approximately $10.97 million.
• Becton, Dickinson's stock is currently down 2.1% and has a market capitalization of $54.85 billion, with a 52-week price range of $163.33 to $251.99.
• In recent earnings, Becton, Dickinson reported $3.68 EPS, surpassing analyst expectations, and anticipates a FY 2025 EPS of 14.300 to 14.450.

Evergreen Capital Management LLC cut its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 47,905 shares of the medical instruments supplier's stock after selling 2,786 shares during the period. Evergreen Capital Management LLC's holdings in Becton, Dickinson and Company were worth $10,973,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of BDX. Smallwood Wealth Investment Management LLC bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $27,000. REAP Financial Group LLC boosted its holdings in Becton, Dickinson and Company by 75.3% in the 4th quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 55 shares during the period. Alpine Bank Wealth Management bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC boosted its holdings in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after purchasing an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA bought a new stake in Becton, Dickinson and Company in the 1st quarter valued at $31,000. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 863 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $192.30, for a total transaction of $165,954.90. Following the sale, the director owned 23,143 shares of the company's stock, valued at $4,450,398.90. This represents a 3.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock traded down $0.98 during mid-day trading on Wednesday, reaching $187.18. 1,780,143 shares of the stock were exchanged, compared to its average volume of 2,607,005. The company has a market cap of $53.65 billion, a price-to-earnings ratio of 33.61, a price-to-earnings-growth ratio of 1.44 and a beta of 0.27. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The firm has a 50-day simple moving average of $183.86 and a 200 day simple moving average of $193.57. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. The business had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. During the same quarter last year, the company posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio is currently 74.82%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Citigroup cut shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and dropped their price objective for the company from $217.00 to $185.00 in a research note on Thursday, May 22nd. Piper Sandler restated a "neutral" rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, Barclays dropped their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Four investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.